Nadya Dimitrova

Nadya Dimitrova

Auto-generated profile, based on publicly available information

Nadya Dimitrova

Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO) , Lyon

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
Gemma GattaGemma Gatta
Gemma Gatta
LBLaura Botta
Laura Botta
SRSilvia Rossi
Silvia Rossi
TATiiu Aareleid
Tiiu Aareleid
MBMagdalena Bielska-Lasota
Magdalena Bielska-Lasota
RPRafael Peris-Bonet
Rafael Peris-Bonet

1 August 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
Gemma GattaGemma Gatta
Gemma Gatta
RCRiccardo Capocaccia
Riccardo Capocaccia
LBLaura Botta
Laura Botta
SMSandra Mallone
Sandra Mallone
RARoberta De Angelis
Roberta De Angelis
EBEllen Benhamou
Ellen Benhamou

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
Gemma GattaGemma Gatta
Gemma Gatta
LBLaura Botta
Laura Botta
María-José SánchezMaría-José Sánchez
María-José Sánchez
LALesley Ann Anderson
Lesley Ann Anderson
Daniela PierannunzioDaniela Pierannunzio
Daniela Pierannunzio
ROR. Otter
R. Otter

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
MSMilena Sant
Milena Sant
MLMaria Dolores Chirlaque Lopez
Maria Dolores Chirlaque Lopez
RARoberto Agresti
Roberto Agresti
María-José SánchezMaría-José Sánchez
María-José Sánchez
BHBernd Holleczek
Bernd Holleczek
ROR. Otter
R. Otter

1 May 2017 in The Lancet Haematology
Verified
Journal Article
Open access
ABAudrey Bonaventure
Audrey Bonaventure
RHRhea Harewood
Rhea Harewood
CSCharles A Stiller
Charles A Stiller
Gemma GattaGemma Gatta
Gemma Gatta
JCJacqueline Clavel
Jacqueline Clavel
LTLf Tanaka
Lf Tanaka
Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia. Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0-14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009. Haematological malignancies were defined by morphology codes in the International Classification of Diseases for Oncology, third revision. We excluded data from registries from which the data were judged to be less reliable, or included only lymphomas, and data from countries in which data for fewer than ten children were available for analysis. We also excluded records because of a missing date of birth, diagnosis, or last known vital status. We estimated 5-year net survival (ie, the probability of surviving at least 5 years after diagnosis, after controlling for deaths from other causes [background mortality]) for children by calendar period of diagnosis (1995-99, 2000-04, and 2005-09), sex, and age at diagnosis (<1, 1-4, 5-9, and 10-14 years, inclusive) using appropriate life tables. We estimated age-standardised net survival for international comparison of survival trends for precursor-cell acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). We analysed data from 89 828 children from 198 registries in 53 countries. During 1995-99, 5-year age-standardised net survival for all lymphoid leukaemias combined ranged from 10·6% (95% CI 3·1-18·2) in the Chinese registries to 86·8% (81·6-92·0) in Austria. International differences in 5-year survival for childhood leukaemia were still large as recently as 2005-09, when age-standardised survival for lymphoid leukaemias ranged from 52·4% (95% CI 42·8-61·9) in Cali, Colombia, to 91·6% (89·5-93·6) in the German registries, and for AML ranged from 33·3% (18·9-47·7) in Bulgaria to 78·2% (72·0-84·3) in German registries. Survival from precursor-cell ALL was very close to that of all lymphoid leukaemias combined, with similar variation. In most countries, survival from AML improved more than survival from ALL between 2000-04 and 2005-09. Survival for each type of leukaemia varied markedly with age: survival was highest for children aged 1-4 and 5-9 years, and lowest for infants (younger than 1 year). There was no systematic difference in survival between boys and girls. Global inequalities in survival from childhood leukaemia have narrowed with time but remain very wide for both ALL and AML. These results provide useful information for health policy makers on the effectiveness of health-care systems and for cancer policy makers to reduce inequalities in childhood cancer survival. Canadian Partnership Against Cancer, Cancer Focus Northern Ireland, Cancer Institute New South Wales, Cancer Research UK, US Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, and the University of Kentucky.

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Open access
LAL.A. Anderson
L.A. Anderson
ATA. Tavilla
A. Tavilla
HBHermann Brenner
Hermann Brenner
SLS. Luttmann
S. Luttmann
CNC. Navarro
C. Navarro
ROR. Otter
R. Otter
European regional variation in cancer survival was reported in the EUROCARE-4 study for patients diagnosed in 1995-1999. Relative survival (RS) estimates are here updated for patients diagnosed with cancer of the oesophagus, stomach and small intestine from 2000 to 2007. Trends in RS from 1999-2001 to 2005-2007 are presented to monitor and discuss improvements in patient survival in Europe. EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1- and 5-year RS. Using registry-specific life-tables stratified by age, gender and calendar year, age-standardised 'complete analysis' RS estimates by country and region were calculated for Northern, Southern, Eastern and Central Europe, and for Ireland and United Kingdom (UK). Survival trends of patients in periods 1999-2001, 2002-2004 and 2005-2007 were investigated using the 'period' RS approach. We computed the 5-year RS conditional on surviving the first year (5-year conditional survival), as the ratio of age-standardised 5-year RS to 1-year RS. Oesophageal cancer 1- and 5-year RS (40% and 12%, respectively) remained poor in Europe. Patient survival was worst in Eastern (8%), Northern (11%) and Southern Europe (10%). Europe-wide, there was a 3% improvement in oesophageal cancer 5-year survival by 2005-2007, with Ireland and the UK (3%), and Central Europe (4%) showing large improvements. Europe-wide, stomach cancer 5-year RS was 25%. Ireland and UK (17%) and Eastern Europe (19%) had the poorest 5-year patient survival. Southern Europe had the best 5-year survival (30%), though only showing an improvement of 2% by 2005-2007. Small intestine cancer 5-year RS for Europe was 48%, with Central Europe having the best (54%), and Ireland and UK the poorest (37%). Five-year patient survival improvement for Europe was 8% by 2005-2007, with Central, Southern and Eastern Europe showing the greatest increases (⩾9%). Survival for these cancer sites, particularly oesophageal cancer, remains poor in Europe with wide variation. Further investigation into the wide variation, including analysis by histology and anatomical sub-site, will yield insights to better monitor and explain the improvements in survival observed over time.